Antiviral therapeutic approaches for sars-cov-2 infection: A systematic review

Gil Martínez V. ; Avedillo Salas A. (Universidad de Zaragoza) ; Santander Ballestín S. (Universidad de Zaragoza)

Resumen: Background: Due to the lack of an etiologic treatment for SARS-CoV-2 and the difficulties involved in developing new drugs, some drugs already approved for other diseases or with efficacy against SARS and MERS, have been used in patients with COVID-19. This systematic review aims to summarize evidence on the efficacy and safety of five antivirals applied to patients with COVID-19, that have proven to be effective either in vitro studies or in studies on SARS-CoV and MERS.; Methods: An intensive search of different databases (Pub Med, WoS, MEDLINE and Cochrane COVID-19 Study Register) has been carried out until the end of April 2021. This systematic review has been conducted according to the PRISMA statement. From each of the included studies, the characteristics of the intervention and comparison groups, demographic data and results were extracted independently; Results: Remdesivir is well tolerated and helps to accelerate clinical improvement but is ineffective in reducing mortality. Favipiravir is safe and shows promising results regarding symptom resolution but does not improve viral clearance. The use of lopinavir/ritonavir has been associated with an increased risk of gastrointestinal adverse events and it has not proven to be effective. No significant differences were observed between patients treated with ribavirin or umifenovir and their respective control groups; Conclusions: Remdesivir and favipiravir are well tolerated and effective in accelerating clinical improvement. This systematic review does not support the use of lopinavir/ritonavir, ribavirin and umifenovir in hospitalized patients with COVID-19.

Idioma: Inglés

DOI: 10.3390/ph14080736

Año: 2021

Publicado en: Pharmaceuticals 14, 8 (2021), 736 [26 pp.]
ISSN: 1424-8247

Factor impacto JCR: 5.215 (2021)

Categ. JCR: PHARMACOLOGY & PHARMACY rank: 69 / 279 = 0.247 (2021) - Q1 - T1
Categ. JCR: CHEMISTRY, MEDICINAL rank: 16 / 63 = 0.254 (2021) - Q2 - T1

Factor impacto CITESCORE: 4.0 - Pharmacology, Toxicology and Pharmaceutics (Q2) - Biochemistry, Genetics and Molecular Biology (Q3)

Factor impacto SCIMAGO: 0.851 - Pharmaceutical Science (Q1) - Drug Discovery (Q1)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Farmacología (Dpto. Farmac.Fisiol.y Med.L.F.)